Developer docs
API playgroundTry for free, no card

Search company profiles

BlinkLab

Full company profile

uuid0002jml

Namestring
BlinkLab
Legal namestring
BlinkLab Limited
Websiteurl
blinklab.org
Company typeenum
Public
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
smartphone diagnostics, autism assessment, ADHD diagnostic, neurobehavioral testing, AI healthcare
Industry6 codes
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYEDAKAKAA
Autism Diagnostic & Educational Assessment Services
Education/Special Education & Learning Support Services/Autism Support Services (Educational)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Child and Youth Services62411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Digital Health Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1BlinkLab Dx1 (Autism Diagnostic)
TypeLicensing Royalties
Description

AI-powered smartphone-based diagnostic aid for autism. Following FDA 510(k) clearance and CE marking, the company plans to commercialize through healthcare systems and specialist centers. Revenue model will likely involve licensing fees to clinical institutions.

blinklab.org
2BlinkLab Dx2 (ADHD Diagnostic)
TypeLicensing Royalties
Description

Diagnostic adjunct for ADHD using the same platform. The company plans to initiate FDA 510(k) registrational trial for Dx2 following Dx1 approval. Will leverage same commercial infrastructure as Dx1.

blinklab.org
3Research Platform Licensing
TypeLicensing Royalties
Description

BlinkLab offers its technology platform to research institutions for remote neurobehavioral testing in clinical studies. The company provides access to its app and online portal, with data retained by BlinkLab as AI training assets.

blinklab.org
4International Screening Programs
TypeLicensing Royalties
Description

Nationwide autism screening agreements with governments or foundations (e.g., Morocco's Foundation Mohammed V for Solidarity) where commercial fees are renegotiated upon FDA clearance.

einpresswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Clinical Study Participant Compensation
ModelOtherBilling cadenceOne-time
Notes

Participants in clinical studies receive a $200 gift card upon completing the diagnostic evaluation (3 videos, 5-15 minutes each plus intake).

blinklab.org
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1BlinkLab Dx1
Description

AI-powered autism diagnostic aid - a smartphone-based neurological assessment designed to provide rapid, accessible, and accurate autism screening for children as young as 18 months old.

blinklab.org
+1 more record
Core offering1 text field

BlinkLab develops and sells an AI-powered smartphone-based neurobehavioral diagnostic platform that uses computer vision and auditory stimuli to objectively measure reflexive responses (eyeblinks, acoustic startle, prepulse inhibition) as biomarkers for autism (Dx1) and ADHD (Dx2). The platform consists of a mobile app (iOS), online research portal, and cloud infrastructure, designed for at-home clinical assessment of children as young as 18 months, with results shared securely with healthcare professionals and researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 83.7% sensitivity and 84.7% specificity in pilot study, exceeding FDA required thresholds of >65% for both metrics
+4 more records
Product overview1 text field

BlinkLab is a digital health company offering a smartphone-based neurobehavioral diagnostic platform for autism and ADHD. The platform consists of a mobile app (iOS), an online research portal, and cloud infrastructure. Two diagnostic modules share this core platform: BlinkLab Dx1 for autism detection (under FDA 510(k) review and CE/MDR approval) and BlinkLab Dx2 for ADHD diagnosis (in development). Both modules use the same smartphone app and portal but employ different digital biomarkers derived from audio-visual neurobehavioral testing. The platform delivers auditory stimuli via headphones while using computer vision to track facial and eyelid responses, providing objective reflex-based measures to support clinicians in assessing neurodevelopmental conditions in children as young as 18 months.

Product and service3 records
1BlinkLab Dx1
CategoryDiagnostic Aid — Autism
Description

AI-powered smartphone-based diagnostic aid for autism that uses computer vision and audio stimuli to measure reflexive eyelid responses (acoustic startle response and prepulse inhibition) as objective biomarkers for autism detection in children as young as 18 months. Currently undergoing FDA 510(k) registrational trial and CE/MDR approval process for licensing to healthcare systems and specialist centers.

2BlinkLab Dx2
CategoryDiagnostic Adjunct — ADHD
Description

ADHD diagnostic adjunct that uses the same smartphone technology, app, and online portal as Dx1 but employs different digital biomarkers generated by a child's interaction with the app to evaluate brain function and detect possible indicators of ADHD. Will leverage the same commercial infrastructure as Dx1 once approved.

3BlinkLab Smartphone Neurobehavioral Testing Platform
CategoryResearch Platform / Diagnostic Infrastructure
Description

Core smartphone-based neurobehavioral testing platform consisting of a mobile app (iOS, requiring iPhone X or newer or iPad 9th generation+, iOS 15.0+), online research portal, and cloud infrastructure. Delivers reflexive tests (acoustic startle response, prepulse inhibition, eyeblink conditioning, habituation) via audio stimuli through headphones while computer vision tracks facial/eyelid responses. Test sessions take approximately 12–20 minutes with children watching engaging videos. Licensed to research institutions for large-scale remote neurobehavioral testing in clinical studies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Academic research agreement expanding into therapy evaluation for neurodevelopmental conditions including autism. Study focuses on APDS (Activated PI3K Delta Syndrome) associated with neurodevelopmental symptoms. Moves BlinkLab beyond diagnostics into therapy monitoring.

2Foundation Mohammed V for Solidarity (Morocco)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Nationwide autism screening agreement to deploy Dx1 smartphone-based screening technology across Morocco's national health system (38 million population). Generates real-world clinical validation data for FDA 510(k) trial. All data retained exclusively by BlinkLab as IP asset.

einpresswire.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-03-01
Description

Contract Research Organisation (CRO) leading and conducting the FDA 510(k) pivotal validation study to ensure full adherence to study protocols and data quality.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Ninth clinical site for pivotal FDA 510(k) trial. Drexel's A.J. Drexel Autism Institute is nationally recognized for population-level autism surveillance, diagnostic access, and evidence-based policy development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Eighth premier US autism center for FDA 510(k) trial of smartphone-based diagnostic aid. Multidisciplinary autism services integrating expert clinicians, evidence-based assessment, and comprehensive family support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Interdisciplinary institute at Vanderbilt University dedicated to advancing autism research. Part of Autism Care Network improving standards of care. Joins FDA 510(k) trial network for autism diagnostic.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Globally recognized leader in pediatric research and innovation in children's health. Center for Child Health, Behavior and Development is pioneer in autism research providing critical insights into early diagnosis and intervention.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

First study evaluating BlinkLab autism detection app in adults and late-diagnosed autism, with emphasis on women. NAR has 6,800 active participants. Part of SCANNER consortium. IRB-approved study with 200 participants commencing April 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Clinical study in patients with spinocerebellar ataxias (SCA) to study effect of aerobic physical exercise on neuroplasticity. Uses BlinkLab eyeblink conditioning test as biomarker for motor learning. Study will recruit up to 62 adults over 18 months.

10Monash University (MAGNET Project)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Collaboration with landmark MAGNET Project enrolling 1,000 families with children diagnosed with autism, ADHD, or both. Study aims to identify data-driven subtypes using deep phenotyping. BlinkLab paying A$389,398 in fees over 24-month term.

blinklab.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Clinical trial partnership for autism diagnosis supporting US and EU regulatory approval. Large autism expertise centre in Netherlands for children, adolescents, adults. Part of SCANNER consortium investigating sex differences in autism.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Strategic partnership with fifth largest outpatient mental health care provider in Europe. Pilot study validated technology in clinical setting for ADHD diagnosis. Preliminary study in 184 participants showed children with ADHD have significantly heightened sensory sensitivity. Exclusive partnership in Netherlands for ADHD, depression and anxiety.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Clinical study on early diagnosis of frontotemporal dementia (FTD) and Alzheimer's using BlinkLab's smartphone-based remote assessment including eyeblink conditioning (EBC) and prepulse inhibition (PPI). Also includes therapy evaluation partnership for APDS neurodevelopmental conditions.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Clinical study to assess BlinkLab smartphone test for Functional Neurological Disorder (FND) diagnosis. Study led by Dr. Olivia Kim recruiting up to 500 patients across Maine, New York, New Jersey over 3 years.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Clinical study in children with autism using AI-powered diagnostic tools. Study involves up to 200 children (100 diagnosed with autism, 100 without) to finalize AI/ML algorithms for larger FDA registration study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

BlinkLab was founded by Princeton University neuroscientists. The original research and development of the smartphone-based neurobehavioral testing platform occurred at Princeton. The company leverages ongoing collaboration with Princeton researchers including Dr. Sam Wang.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Cognoa is the closest direct competitor: it has already secured FDA clearance for an AI-powered autism diagnostic (Canvas Dx) using a smartphone-based approach, occupying the exact regulatory and clinical niche BlinkLab is targeting.

TypeDirect peer
Description

EarliTec has FDA-cleared eye-tracking-based autism diagnostic tools, making it a direct US regulatory and commercial competitor in objective, technology-mediated autism assessment.

TypeDirect peer
Description

Qbtech provides FDA-cleared objective ADHD testing (QbTest), directly comparable to BlinkLab's planned Dx2 ADHD diagnostic adjunct that uses the same sensorimotor gating biomarker concept.

TypeDirect peer
Description

Akili is a publicly-traded digital therapeutics company with FDA-cleared products in ADHD (EndeavorRx), sharing BlinkLab's digital therapeutic / SaMD regulatory pathway and pediatric neurodevelopmental focus.

TypeEmerging player
Description

Altoida uses smartphone-based digital biomarkers and AI for early detection of cognitive decline and Alzheimer's, sharing BlinkLab's computer-vision-measures-neurometrics technology architecture but focused on neurodegeneration rather than neurodevelopment.

TypeEmerging player
Description

Linus Health applies smartphone- and tablet-based digital cognitive assessments with AI/ML for early detection of dementia, paralleling BlinkLab's smartphone-first, computer-vision-driven biomarker model in an adjacent neurology category.

TypeEmerging player
Description

Behavior Imaging Solutions offers remote autism assessment and telebehavioral health tools, competing in the same remote autism evaluation workflow that BlinkLab's Dx1 is designed to enable.

TypeEmerging player
Description

Quadrant Biosciences develops multi-modality diagnostics (including epigenetic saliva-based tests) for autism and ADHD, serving the same clinical need for objective pediatric neurodevelopmental assessment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BlinkLab

Digital Health Diagnosticsblinklab.org

BlinkLab firmographics

Firmographics
Name
BlinkLab
Legal name
BlinkLab Limited
Website
https://blinklab.org
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

BlinkLab industry classification

Industry
Product category
Digital Health Diagnostics
NAICS
Child and Youth Services (62411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYEDAKAKAA
Autism Diagnostic & Educational Assessment Services
Education/Special Education & Learning Support Services/Autism Support Services (Educational)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Smartphone diagnostics
  • Autism assessment
  • ADHD diagnostic
  • Neurobehavioral testing
  • AI healthcare

Where BlinkLab is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices4 records

Markets served

BlinkLab business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. BlinkLab Dx1 (Autism Diagnostic): AI-powered smartphone-based diagnostic aid for autism. Following FDA 510(k) clearance and CE marking, the company plans to commercialize through healthcare systems and specialist centers. Revenue model will likely involve licensing fees to clinical institutions.
  2. BlinkLab Dx2 (ADHD Diagnostic): Diagnostic adjunct for ADHD using the same platform. The company plans to initiate FDA 510(k) registrational trial for Dx2 following Dx1 approval. Will leverage same commercial infrastructure as Dx1.
  3. Research Platform Licensing: BlinkLab offers its technology platform to research institutions for remote neurobehavioral testing in clinical studies. The company provides access to its app and online portal, with data retained by BlinkLab as AI training assets.
  4. International Screening Programs: Nationwide autism screening agreements with governments or foundations (e.g., Morocco's Foundation Mohammed V for Solidarity) where commercial fees are renegotiated upon FDA clearance.

Pricing tiers

ModelBillingPrice
OtherOne-timeClinical Study Participant Compensation

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

BlinkLab product offering

Product offering

Core offering

BlinkLab develops and sells an AI-powered smartphone-based neurobehavioral diagnostic platform that uses computer vision and auditory stimuli to objectively measure reflexive responses (eyeblinks, acoustic startle, prepulse inhibition) as biomarkers for autism (Dx1) and ADHD (Dx2). The platform consists of a mobile app (iOS), online research portal, and cloud infrastructure, designed for at-home clinical assessment of children as young as 18 months, with results shared securely with healthcare professionals and researchers.

Product overview

BlinkLab is a digital health company offering a smartphone-based neurobehavioral diagnostic platform for autism and ADHD. The platform consists of a mobile app (iOS), an online research portal, and cloud infrastructure. Two diagnostic modules share this core platform: BlinkLab Dx1 for autism detection (under FDA 510(k) review and CE/MDR approval) and BlinkLab Dx2 for ADHD diagnosis (in development). Both modules use the same smartphone app and portal but employ different digital biomarkers derived from audio-visual neurobehavioral testing. The platform delivers auditory stimuli via headphones while using computer vision to track facial and eyelid responses, providing objective reflex-based measures to support clinicians in assessing neurodevelopmental conditions in children as young as 18 months.

Differentiator

Problem solved

Functional benefit

Brands

  • BlinkLab Dx1: AI-powered autism diagnostic aid - a smartphone-based neurological assessment designed to provide rapid, accessible, and accurate autism screening for children as young as 18 months old.
  • BlinkLab Dx2

Products and services

  • BlinkLab Dx1 AI-powered smartphone-based diagnostic aid for autism that uses computer vision and audio stimuli to measure reflexive eyelid responses (acoustic startle response and prepulse inhibition) as objective biomarkers for autism detection in children as young as 18 months. Currently undergoing FDA 510(k) registrational trial and CE/MDR approval process for licensing to healthcare systems and specialist centers.
  • BlinkLab Dx2 ADHD diagnostic adjunct that uses the same smartphone technology, app, and online portal as Dx1 but employs different digital biomarkers generated by a child's interaction with the app to evaluate brain function and detect possible indicators of ADHD. Will leverage the same commercial infrastructure as Dx1 once approved.
  • BlinkLab Smartphone Neurobehavioral Testing Platform Core smartphone-based neurobehavioral testing platform consisting of a mobile app (iOS, requiring iPhone X or newer or iPad 9th generation+, iOS 15.0+), online research portal, and cloud infrastructure. Delivers reflexive tests (acoustic startle response, prepulse inhibition, eyeblink conditioning, habituation) via audio stimuli through headphones while computer vision tracks facial/eyelid responses. Test sessions take approximately 12–20 minutes with children watching engaging videos. Licensed to research institutions for large-scale remote neurobehavioral testing in clinical studies.

Quantifiable outcome

  • 83.7% sensitivity and 84.7% specificity in pilot study, exceeding FDA required thresholds of >65% for both metrics
  • +4 more outcomes

Companies that use BlinkLab

Customer profile

Named customers13 records

Segments5 records

Ideal customer profiles4 records

BlinkLab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

BlinkLab partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered supporting and core.

  • Erasmus MC (Therapy Evaluation)supportingStrategic or Co-development Partner · 1 May 2026Academic research agreement expanding into therapy evaluation for neurodevelopmental conditions including autism. Study focuses on APDS (Activated PI3K Delta Syndrome) associated with neurodevelopmental symptoms. Moves BlinkLab beyond diagnostics into therapy monitoring.
  • Foundation Mohammed V for Solidarity (Morocco)coreStrategic or Co-development Partner · 1 March 2026Nationwide autism screening agreement to deploy Dx1 smartphone-based screening technology across Morocco's national health system (38 million population). Generates real-world clinical validation data for FDA 510(k) trial. All data retained exclusively by BlinkLab as IP asset.
  • IQVIA-MCRAcoreImplementation/ SI/ Consulting Partner · 1 March 2026Contract Research Organisation (CRO) leading and conducting the FDA 510(k) pivotal validation study to ensure full adherence to study protocols and data quality.
  • Drexel UniversitycoreStrategic or Co-development Partner · 1 February 2026Ninth clinical site for pivotal FDA 510(k) trial. Drexel's A.J. Drexel Autism Institute is nationally recognized for population-level autism surveillance, diagnostic access, and evidence-based policy development.
  • Rush University Medical CentercoreStrategic or Co-development Partner · 1 November 2025Eighth premier US autism center for FDA 510(k) trial of smartphone-based diagnostic aid. Multidisciplinary autism services integrating expert clinicians, evidence-based assessment, and comprehensive family support.
  • Vanderbilt Kennedy CentercoreStrategic or Co-development Partner · 1 September 2025Interdisciplinary institute at Vanderbilt University dedicated to advancing autism research. Part of Autism Care Network improving standards of care. Joins FDA 510(k) trial network for autism diagnostic.
  • Seattle Children's Research InstitutecoreStrategic or Co-development Partner · 1 September 2025Globally recognized leader in pediatric research and innovation in children's health. Center for Child Health, Behavior and Development is pioneer in autism research providing critical insights into early diagnosis and intervention.
  • Netherlands Autism Register (NAR) / VU AmsterdamcoreStrategic or Co-development Partner · 1 March 2025First study evaluating BlinkLab autism detection app in adults and late-diagnosed autism, with emphasis on women. NAR has 6,800 active participants. Part of SCANNER consortium. IRB-approved study with 200 participants commencing April 2025.
  • Columbia UniversitycoreStrategic or Co-development Partner · 1 November 2024Clinical study in patients with spinocerebellar ataxias (SCA) to study effect of aerobic physical exercise on neuroplasticity. Uses BlinkLab eyeblink conditioning test as biomarker for motor learning. Study will recruit up to 62 adults over 18 months.
  • Monash University (MAGNET Project)coreStrategic or Co-development Partner · 1 November 2024Collaboration with landmark MAGNET Project enrolling 1,000 families with children diagnosed with autism, ADHD, or both. Study aims to identify data-driven subtypes using deep phenotyping. BlinkLab paying A$389,398 in fees over 24-month term.
  • INTER-PSYcoreStrategic or Co-development Partner · 1 September 2024Clinical trial partnership for autism diagnosis supporting US and EU regulatory approval. Large autism expertise centre in Netherlands for children, adolescents, adults. Part of SCANNER consortium investigating sex differences in autism.
  • Mental Care GroupcoreStrategic or Co-development Partner · 1 July 2024Strategic partnership with fifth largest outpatient mental health care provider in Europe. Pilot study validated technology in clinical setting for ADHD diagnosis. Preliminary study in 184 participants showed children with ADHD have significantly heightened sensory sensitivity. Exclusive partnership in Netherlands for ADHD, depression and anxiety.
  • Erasmus University Medical CentercoreStrategic or Co-development Partner · 1 June 2024Clinical study on early diagnosis of frontotemporal dementia (FTD) and Alzheimer's using BlinkLab's smartphone-based remote assessment including eyeblink conditioning (EBC) and prepulse inhibition (PPI). Also includes therapy evaluation partnership for APDS neurodevelopmental conditions.
  • Bates CollegesupportingStrategic or Co-development Partner · 1 June 2024Clinical study to assess BlinkLab smartphone test for Functional Neurological Disorder (FND) diagnosis. Study led by Dr. Olivia Kim recruiting up to 500 patients across Maine, New York, New Jersey over 3 years.
  • Turning Pointe Autism FoundationcoreStrategic or Co-development Partner · 1 May 2024Clinical study in children with autism using AI-powered diagnostic tools. Study involves up to 200 children (100 diagnosed with autism, 100 without) to finalize AI/ML algorithms for larger FDA registration study.
  • Princeton UniversitycoreStrategic or Co-development Partner · 1 November 2021BlinkLab was founded by Princeton University neuroscientists. The original research and development of the smartphone-based neurobehavioral testing platform occurred at Princeton. The company leverages ongoing collaboration with Princeton researchers including Dr. Sam Wang.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

BlinkLab competitors and assessment

Company assessment

Direct peers

  • Cognoa: Cognoa is the closest direct competitor: it has already secured FDA clearance for an AI-powered autism diagnostic (Canvas Dx) using a smartphone-based approach, occupying the exact regulatory and clinical niche BlinkLab is targeting.
  • EarliTec Diagnostics: EarliTec has FDA-cleared eye-tracking-based autism diagnostic tools, making it a direct US regulatory and commercial competitor in objective, technology-mediated autism assessment.
  • Qbtech: Qbtech provides FDA-cleared objective ADHD testing (QbTest), directly comparable to BlinkLab's planned Dx2 ADHD diagnostic adjunct that uses the same sensorimotor gating biomarker concept.
  • Akili Interactive: Akili is a publicly-traded digital therapeutics company with FDA-cleared products in ADHD (EndeavorRx), sharing BlinkLab's digital therapeutic / SaMD regulatory pathway and pediatric neurodevelopmental focus.

Emerging players

  • Altoida: Altoida uses smartphone-based digital biomarkers and AI for early detection of cognitive decline and Alzheimer's, sharing BlinkLab's computer-vision-measures-neurometrics technology architecture but focused on neurodegeneration rather than neurodevelopment.
  • Linus Health: Linus Health applies smartphone- and tablet-based digital cognitive assessments with AI/ML for early detection of dementia, paralleling BlinkLab's smartphone-first, computer-vision-driven biomarker model in an adjacent neurology category.
  • Behavior Imaging Solutions: Behavior Imaging Solutions offers remote autism assessment and telebehavioral health tools, competing in the same remote autism evaluation workflow that BlinkLab's Dx1 is designed to enable.
  • Quadrant Biosciences: Quadrant Biosciences develops multi-modality diagnostics (including epigenetic saliva-based tests) for autism and ADHD, serving the same clinical need for objective pediatric neurodevelopmental assessment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

BlinkLab social profiles

Digital presence

BlinkLab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BlinkLab leadership team

Management profile

Number of profiles

Profiles10 records

BlinkLab funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BlinkLab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BlinkLab

What does BlinkLab do?

BlinkLab develops and sells an AI-powered smartphone-based neurobehavioral diagnostic platform that uses computer vision and auditory stimuli to objectively measure reflexive responses (eyeblinks, acoustic startle, prepulse inhibition) as biomarkers for autism (Dx1) and ADHD (Dx2). The platform consists of a mobile app (iOS), online research portal, and cloud infrastructure, designed for at-home clinical assessment of children as young as 18 months, with results shared securely with healthcare professionals and researchers.

Is BlinkLab a public or private company?

BlinkLab is a public company. It is classified as public and is currently operating.

When was BlinkLab founded?

BlinkLab was founded in 2021. It employs 11 to 50 people.

Where is BlinkLab based?

BlinkLab is headquartered in Leiden, Netherlands, in the Europe region.

How does BlinkLab make money?

Four revenue lines are on record. BlinkLab Dx1 (Autism Diagnostic) is the primary driver. The others are blinkLab Dx2 (ADHD Diagnostic), research Platform Licensing and international Screening Programs.

Who are BlinkLab's main competitors?

Direct peers on record are Cognoa, EarliTec Diagnostics, Qbtech and Akili Interactive. Emerging players are Altoida, Linus Health, Behavior Imaging Solutions and Quadrant Biosciences.

Does BlinkLab have an API?

No public API is recorded for BlinkLab.

What industry is BlinkLab in?

BlinkLab's product category is Digital Health Diagnostics. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 62411 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coBlinkLab lands $819K Australian tax refund for autism diagnostic work | Dealroom NewsBlinkLab received a $789,200 non-dilutive refund from Australia's R&D tax incentive program, announced November 19, 2026. The funds support its US pivotal study and FDA submission, expected in Q1 2027. The refund supplements a $10.5M cash balance and follows a $11.3M share placement.The future of tradingBlinklab Requests Trading HaltBlinkLab Ltd has requested a trading halt pending the announcement of results from its Shank2 autism study. The company's stock is listed on the Australian exchange under ticker BB1.AX. No further details on the study results were disclosed.Mirage NewsBlinkLab Launches Key FDA Test for AI Autism AppBlinkLab Limited reported 82% sensitivity and 83% specificity in a European study of its smartphone-based ADHD assessment technology, BlinkLab Dx2, involving 208 children aged 6-17. The study demonstrated that the AI-driven platform could correctly identify children with and without ADHD by capturing involuntary behaviours via smartphone, with results comparable to clinical assessment. The company plans to use these findings to initiate a US pilot study and pursue FDA registrational approval, representing an early-stage but strategically significant expansion beyond its core autism diagnostic program into a larger addressable market.ProactiveinvestorsBlinkLab ADHD study delivers strong results and opens pathway beyond autismBlinkLab Ltd has reported positive results from a European multicentre ADHD study involving 375 children, achieving 82% sensitivity and 83% specificity in identifying children aged 6 to 17 with the condition. The study, conducted in collaboration with Mental Care Group in the Netherlands, analyzed data from 208 children and demonstrated the feasibility of using smartphone-based measurements to detect digital neurobehavioural biomarkers associated with ADHD. The company now plans to initiate a US pilot study followed by a prospective FDA registrational study for its BlinkLab Dx2 product, following a development strategy similar to its autism-focused BlinkLab Dx1.SfariUnbiased Approaches to Quantifying Motor and Other Visible Behaviors in Humans with AutismThe Simons Foundation Autism Research Initiative (SFARI) convened a workshop to explore advanced quantitative phenotyping methods for capturing visible behaviors in humans and animals with autism. Presentations highlighted the use of computer vision, smartphone-based assessments like BlinkLab, and AI platforms such as Storyline Health to identify motor signatures and improve diagnostic accuracy. The discussions emphasized the need for accessible, unbiased tools and cross-species studies to better understand autism heterogeneity and guide early intervention.MobiHealthNews$13M raised for autism diagnostics AI and more briefsThree medtech developments were reported: ASX-listed BlinkLab raised A$17.5 million ($12.6 million) via an oversubscribed placement to fund a pivotal trial for FDA 510(k) clearance and CE marking of its AI-powered autism diagnostic aid (BlinkLab Dx1), as well as US clinical studies for an ADHD diagnostic adjunct (BlinkLab Dx2). Separately, Australian startup Lumonus partnered with New York-based Memorial Sloan Kettering Cancer Center to co-develop MSK's mathematical optimization engine into Lumonus's radiation oncology workflow and treatment planning platform. The New South Wales government also awarded A$7.4 million ($5.3 million) through its Medical Devices Fund to four medtech companies, including Baymatob, which is developing an AI-powered maternal-foetal early warning platform.Small CapsBlinkLab Raises A$17.5m to Fund FDA Autism Diagnostic Clearance and Advance ADHD TrialsBlinkLab (ASX: BB1) has raised A$17.5 million through an oversubscribed placement at A$0.65 per share to fund pivotal FDA 510(k) clearance trials for its autism diagnostic aid Dx1 and launch clinical trials for ADHD using its Dx2 platform. The company's Dx1 has been selected for Morocco's government-funded nationwide autism screening program starting April 2026, where BlinkLab retains ownership of generated data and expects no material capital expenditure. The FDA 510(k) pivotal validation study for Dx1 has commenced with the first participant enrolled, targeting an FDA submission by end-2026, with prior pilot data reportedly exceeding FDA-agreed performance thresholds.LinkedInAI-Powered Treatment Revolution in Diabetes, Mental Health & RecoveryThis intelligence brief summarizes five major healthcare developments from March 2026: FDA approved J&J's ICOTYDE as the first oral peptide for plaque psoriasis, marking a shift from specialty injectables to oral medications; India introduced new Clinical Trial Rules reducing regulatory review timelines from 90 to 45 days to accelerate R&D; FDA granted PMA approval for LivaNova's aura6000 neurostim system for sleep apnea; BlinkLab enrolled the first participant in a pivotal FDA study for a smartphone-based AI diagnostic for autism; and Danaher finalized its $9.9 billion acquisition of Masimo to integrate remote monitoring into its life sciences portfolio. The article frames these developments as part of a broader 'De-institutionalization' trend, moving diagnostics to smartphones, biologics to oral formulations, and regulatory processes to digital platforms.